To identify pharmacological interventions that could mitigate the harmful effects of mutations and alleviate associated pathological symptoms, we selected the R329H mutation as a representative of CMT-related AlaRS mutants in the aminoacylation domain for our drug screening. This evidence concerns the gene AARS1 and Charcot-Marie-Tooth disease.